EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and EXXEL PHARMA, INC for FAAH Inhibitors UC Cases 2001-104 and 2014-360 UC Agreement Control No.:2022-04-0094Exclusive License Agreement • September 19th, 2025 • Exxel Pharma, INC. • Pharmaceutical preparations
This amended and restated exclusive license agreement- global FAAH inhibitors (“Agreement”) is made effective this 17th day of August, 2021 (“Effective Date”), by and between The Regents of the University of California, a California public corporation, having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (“The Regents”), acting through its frvine campus having an address at University of California, hvine, Invention Transfer Group, 5270 California Ave., Suite 100, frvine, CA 92697-7700 (“UCI”) and Exxel Phruma Inc., having a p1incipal place of business at 12635 E Montview Blvd, Suite 137, Aurora, CO 80045 (“Licensee”).
EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and EXXEL PHARMA, INC for Peripheral FAAH Inhibitors UC Cases 2001-104, 2008-522, 2012-075, and 2014-360 UC Agreement Control No.:2022-04-0096Exclusive License Agreement • September 19th, 2025 • Exxel Pharma, INC. • Pharmaceutical preparations
This amended and restated exclusive license agreement – peripherally restricted FAAH inhibitors (“Agreement”) is made effective this 17th day of August, 2021 (“Effective Date”), by and between The Regents of the University of California, a California public corporation, having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (“The Regents”), acting through its Irvine campus having an address at University of California, Irvine, Invention Transfer Group, 5270 California Ave., Suite 100, Irvine, CA 92697-7700 (“UCI”) and Exxel Pharma Inc., having a principal place of business at 12635 E Montview Blvd, Suite 134, Aurora, CO 80045 (“Licensee”).